Difference between revisions of "Vinblastine (Velban)"

Revision as of 16:37, 17 June 2022

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Patient drug information

Diseases for which it is used

Diseases for which it was used

History of changes in FDA indication

11/25/1965: Initial approval
Uncertain date: Approved for generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system).
Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated).
Uncertain date: Approved for histiocytic lymphoma.
Uncertain date: Approved for mycosis fungoides (advanced stages).
Uncertain date: Approved for advanced carcinoma of the testis. (Based on Loehrer et al. 1988)
Uncertain date: Approved for Kaposi's sarcoma.
Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X).
Uncertain date: Approved for choriocarcinoma resistant to other chemotherapeutic agents.
Uncertain date: Approved for carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.

Also known as

Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
Brand names:

Synonyms
Alkaban-AQ	Blastovin	Cellblastin	Cytoblastine	Erbablas
Exal	Faulblastina	Lemblastine	Periblastine	Rabinefil
Velban	Velbastine	Velbe	Vinblasin	Vinblastin
Vinblastina

References

[insert-1] 1.0 ^1.1 Vinblastine (Velban) package insert

[2] Vinblastine (Velban) package insert (locally hosted backup)

[3] Vinblastine (Velban) patient drug information (Chemocare)

[4] Vinblastine (Velban) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 33: / Line 33: @@
 ==History of changes in FDA indication==
-/25/1965: Initial approval
+*11/25/1965: Initial approval
+*Uncertain date: Approved for generalized [[Hodgkin lymphoma|Hodgkin's disease]] (Stages III and IV, Ann Arbor modification of Rye staging system).
+*Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated).
+*Uncertain date: Approved for histiocytic lymphoma.
+*Uncertain date: Approved for [[cutaneous T-cell lymphoma|mycosis fungoides]] (advanced stages).
+*Uncertain date: Approved for [[testicular cancer|advanced carcinoma of the testis]]. ''(Based on Loehrer et al. 1988)''
+*Uncertain date: Approved for [[Kaposi sarcoma|Kaposi's sarcoma]].
+*Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X).
+*Uncertain date: Approved for [[Gestational trophoblastic neoplasia|choriocarcinoma resistant to other chemotherapeutic agents]].
+*Uncertain date: Approved for [[breast cancer|carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy]].
 ==Also known as==